AUPH 7.18 Aurinia Pharmaceuticals Inc.
| Range: | 4.71-10.05 | Vol Avg: | 1379446 | Last Div: | 0 | Changes: | 0.1 |
| Beta: | 1.45 | Cap: | 1.01B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed Sep 03 2014 | Empoloyees: | 300 | ||
| CUSIP: | 05156V102 | CIK: | 0001600620 | ISIN: | CA05156V1022 | Country: | CA |
| CEO: | Mr. Peter S. Greenleaf M.B.A. | Website: | https://www.auriniapharma.com | ||||
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Stock Details
AUPH 13
H.C. Wainwright Reiterates Buy Rating on Aurinia Pharmaceuticals (AUPH)
Ed Arce·Fri Sep 06 2024
H.C. Wainwright
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow